Last day of trading in warrants of series TO 6 B is today February 2, 2024

Lund, Sweden - Today, February 2, 2024, is the last day of trading in warrants of series TO 6 B, which were issued in connection with Clinical Laserthermia Systems AB's ("CLS" or the "Company") preferential rights issue of units resolved by the extraordinary general meeting on June 8, 2023. The exercise period runs until and including February 6, 2024.

Each warrant of series TO 6 B entitles the holder to subscribe for one (1) new B-share in CLS at a price of SEK 0.10 per share during the exercise period that started on January 23, 2024 and runs until and including February 6, 2024.

For warrants not to expire worthless, warrant holders must subscribe for new B-shares, with the support of warrants, 17:00 CET on February 6, 2024, at the latest, alternatively sell warrants no later than today, February 2, 2024.

Information brochures about the Company and the offer (in Swedish and English) and other material for investors are available on CLS, Sedermera Corporate Finance AB's, Redeye AB's and Nordic Issuing AB's respective websites (www.clinicallaser.se, www.sedermera.se, www.redeye.se, www.nordic-issuing.se). Complete terms and conditions and instructions for warrants of series TO 6 B are available on the Company's website.

For more information about the warrants of series TO 6 B, please contact:

Sedermera Corporate Finance AB

Phone: +46 40 615 14 10

E-mail: cf@sedermera.se

Website: www.sedermera.se

Redeye AB

Phone: +46 (0)8 545 013 30

E-mail: info@redeye.se

Website: www.redeye.se

For more information about CLS, please contact:

Dan J Mogren, CEO, Clinical Laserthermia Systems AB (publ)

Phone: +46 (0) 70-590 11 40

E-mail: dan.mogren@clinicallaser.com

Website: www.clinicallaser.se

This press release has been translated from Swedish. The Swedish text shall govern for all purposes and prevail in case of any discrepancy with the English version.

About CLS

Clinical Laserthermia Systems AB (publ) develops and sells the TRANBERG®|Thermal Therapy Systems, including Thermoguide Workstation and sterile disposables, for minimally invasive treatment of cancer tumors and drug-resistant epilepsy, according to regulatory approvals in the EU and the US. The products are marketed for image-guided laser ablation and used in studies for treatment with imILT®, the Company's interstitial laser thermotherapy for immunostimulatory ablation with potential abscopal effects. CLS is headquartered in Lund and has subsidiaries in Germany, the US and Singapore. CLS is listed on the Nasdaq First North Growth Market under the symbol CLS B. The Certified Advisor (CA) is FNCA Sweden AB.

For more information about CLS, please visit the Company's website: www.clinicallaser.se